Table 3. . Median fluorescence intensity ratios for cell lines and patient samples.
| Antibodies | Cell lines | Patient samples (by rs1259419 genotype) | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| HL-60 (CC) | Molm-13 (CC) | MV4;11 (CT) | K562 (TT) | CD14-CD45dimCD34+ AML progenitor cells | CD14+ monocytes | |||||
| CC (n = 5) | CT (n = 5) | TT (n = 4) | CC (n = 5) | CT (n = 5) | TT (n = 4) | |||||
| P67.6 | 8.4 | 17.6 | 9.4 | 1.6 | 2.9 | 2.0 | 2.2 | 9.3 | 6.0 | 3.7 |
| HL2541 | 1.1 | 1.4 | 2.3 | 68.9 | 2.3 | 1.3 | 2.4 | 16.3 | 14.4 | 18.2 |
| 5C11–2 | 1.0 | 1.2 | 1.3 | 1.2 | 1.2 | 1.2 | 1.5 | 3.3 | 2.0 | 2.3 |
AML: Acute myeloid leukemia; CC: Homozygous dominant; CT: Heterozygous; MFI: Median fluorescence intensity; TT: Homozygous recessive.